Comparing Aromatase Inhibitors to Tamoxifen in Postmenopausal Women With Breast Cancer
Tamoxifen and aromatase inhibitors are the mainstay of therapy for women with hormone receptor–positive breast cancer (HRP BC), but what about for postmenopausal women with HRP BC and advanced disease? Is there an advantage of one drug over another in this patient group? Read more.

Which Patients on Long-Term Trastuzumab Need Cardiac Monitoring?
Trastuzumab’s product labeling carries a black box warning about the potential for the development of drug-induced cardiomyopathy in patients receiving the biological for breast cancer (BC). However, guidelines are less clear on how to manage patients on continuous trastuzumab for metastatic BC. Read more.

Role of Chemotherapy After Local Therapy in Older Women With Triple-Negative BC
Currently, about one-quarter of breast cancers (BCs) are diagnosed in women aged 70 to 84 years. Although older women typically have hormonally responsive disease, about 12% to 17% of BCs in the United States are triple-negative BC. There are limited data about the management of triple-negative BC in older woman. Read more.